10-K: Calidi Biotherapeutics Reports on Capital Structure, Clinical Programs in Annual 10-K Filing

Calidi Biotherapeutics outlines its capital structure, clinical trial progress, and regulatory landscape in its annual 10-K filing, highlighting both opportunities and challenges for its novel immuno-oncology platforms.

Summary

• Calidi Biotherapeutics, an immuno-oncology company, filed its annual 10-K report detailing its capital stock, warrants, and financial performance.
• As of March 28, 2025, the company had 30,267,580 shares of common stock outstanding, including 28,467,580 shares of voting common stock and 1,800,000 shares of non-voting common stock held in escrow.
• The company also had 1,150,000 public warrants, 191,217 private placement warrants, and 9,881,941 other warrants outstanding.
• The company's authorized capital stock consists of 330,000,000 shares of common stock and 1,000,000 shares of preferred stock, each with a par value of $0.0001 per share.
• The company is developing two stem cell-based platforms (NeuroNova and SuperNova) and one enveloped vaccinia virus platform (RTNova) to deliver oncolytic viruses to cancer patients.
• The lead product candidates include CLD-101 for high-grade glioma (HGG), CLD-201 for solid tumors, and CLD-400 for lung cancer and metastatic solid tumors.
• The company filed an IND application with the FDA for CLD-201 in March 2025 and anticipates commencing a Phase 1 clinical trial in the first half of 2025.
• The company is also engaged in early discovery research involving Adult Allogeneic Adipose-derived (AAA) stem cells for various indications and therapies.
• The company faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies in the immuno-oncology market.
• The company's manufacturing process involves complex steps and relies on external CMOs, with plans to potentially establish its own cGMP manufacturing facilities.
• The company intends to retain significant development and commercial rights to its product candidates and commercialize them on its own or with a partner.
• The company's commercial success depends on its ability to obtain and maintain patent protection and operate without infringing on the proprietary rights of others.
• The company has in-licensed a patent family from the University of Chicago for cancer therapies using an oncolytic adenovirus in combination with a clinical-grade allogeneic neural stem cell line.
• The company is subject to extensive government regulations, including the FD&C Act, PHS Act, and other federal, state, and foreign statutes and regulations.
• The company is also subject to various healthcare laws, including anti-kickback, false claims, and patient data privacy and security laws.
• The company's ability to obtain regulatory approvals and commercialize its product candidates depends on various factors, including clinical trial results, manufacturing capabilities, and market acceptance.
• The company is an emerging growth company and a smaller reporting company, which allows it to take advantage of certain exemptions and reduced reporting requirements.
• The company has identified a going concern issue due to recurring losses from operations and the need for additional funding.

Sentiment

Score: 5

Explanation: The document presents a balanced view, highlighting both the potential of the company's technology and the significant challenges it faces, including financial constraints and regulatory hurdles.

Positives

• The company is developing novel immuno-oncology platforms with the potential to improve cancer treatment.
• The company has a pipeline of product candidates targeting various types of cancer.
• The company has in-licensed intellectual property from reputable institutions.
• The company is actively pursuing clinical development and has filed an IND application for CLD-201.
• The company has a strategic collaboration with Northwestern University for CLD-101.
• The company is exploring opportunities to expand its stem cell production capabilities and out-license stem cell-derived products.

Negatives

• The company has a limited operating history and has not generated any revenue from product sales.
• The company has incurred significant operating losses since its inception and anticipates continued losses for the foreseeable future.
• The company needs to raise substantial additional funding and may be forced to delay, reduce, or eliminate some or all of its product development programs if it cannot secure funding.
• The company faces intense competition from major pharmaceutical and biotechnology companies.
• The company is subject to extensive government regulations and healthcare laws.
• The company has identified a going concern issue due to recurring losses from operations and the need for additional funding.

Risks

• The company's product candidates may not receive regulatory approval or achieve market acceptance.
• The company may face product liability claims.
• The company may be subject to intellectual property infringement claims.
• The company may face difficulties in managing its growth and maintaining effective internal controls.
• The company's reliance on third parties for manufacturing and clinical trials poses risks.
• The company's financial condition and results of operations may be affected by changes in healthcare laws and regulations.
• The company's business may be affected by unstable global economic and geopolitical conditions.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its product candidates through clinical development and seeks regulatory approval.

Industry Context

The company operates in the competitive immuno-oncology market, facing competition from major pharmaceutical and biotechnology companies developing viral immunotherapies.

Comparison to Industry Standards

• The document mentions T-VEC (Imlygic) as the only oncolytic virus therapy with marketing approval in the United States, setting a benchmark for Calidi's own oncolytic virus platform.
• The document references several companies developing viral immunotherapies, including Oncorus, Replimune Group, Amgen, ImmVira Co., IconOVir Bio, Candel Therapeutics, CG Oncology, Genelux Corporation, Imugene Limited, Oncolytics Biotech Inc., and FerGene, Inc., indicating the competitive landscape and the need for Calidi to differentiate its products.

Corporate Governance

Legal Proceedings

• The company is involved in a lawsuit with certain physicians regarding stock options.
• The company is involved in a lawsuit with its former Chief Accounting Officer and interim Chief Financial Officer alleging defamation and constructive discharge.
• The company is involved in a lawsuit related to securities fraud in violation of the California Corporations Code, breach of covenant of good faith and fair dealing, unjust enrichment, restitution, breach of fiduciary duty, and constructive fraud.

Related Party Transactions

• The company has engaged in various related-party transactions, including investments from its largest investor and Chief Executive Officer and Chairman of the Board of Directors.
• The company has entered into a loan agreement with a relative of an officer.
• The company has entered into a subscription agreement with an accredited investor, a related-party.

Stakeholder Impact

• The company's financial condition and future prospects are uncertain, which could impact stakeholders, including shareholders, employees, and creditors.
• The company's ability to develop and commercialize its product candidates could impact patients with cancer.

Next Steps

• Advancing CLD-101 in a Phase 1b/Phase 2 clinical trial for the treatment of newly diagnosed HGG.
• Advancing CLD-101 in a Phase 1 clinical trial in patients with recurrent HGG.
• Entering into a Phase 1 clinical trial in patients with breast cancer, head & neck squamous cell carcinoma (HNSCC), and soft tissue sarcoma, pending the acceptance of the company's IND application filed in March 2025.

Key Dates

Keywords

immuno-oncology, oncolytic virus, stem cell therapy, clinical trials, regulatory approval, biopharmaceutical, warrants, capital stock, intellectual property, manufacturing, licensing, FDA, clinical development, financing, healthcare